Rajshekhar Chakraborty

Oct 15, 2024 | nature.com | Ghulam Rehman Mohyuddin |Rajshekhar Chakraborty |Samer Al Hadidi

Dear Editor,Humans rely on heuristics to simplify decision-making [1] and often use chronological age as a key factor. However, chronological age may not accurately reflect an individual’s physiological age and functional performance [2]. A notable heuristic in decision-making is left-digit bias, where humans tend to categorize decisions based on the left-most digit of a continuous variable (e.g., age, blood pressure) [3].

Sep 10, 2024 | onlinelibrary.wiley.com | Rajshekhar Chakraborty

To the Editor: With the advent of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (CD38mAbs), the outcomes of transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (MM) have substantially improved in the last decade.1-3 Currently, there are two widely accepted standard-of-care regimens in newly diagnosed TIE MM: daratumumab-lenalidomide-dexamethasone (DRd) and bortezomib-lenalidomide-dexamethasone (VRd), based on the MAIA...

Aug 11, 2024 | nature.com | Rajshekhar Chakraborty |Aniko Szabo |Carolina Schinke |Binod Dhakal |Ghulam Rehman Mohyuddin |Martin Kaiser | +1 more

To the Editor:Bispecific antibodies [bsAb] targeting B-cell maturation antigen [BCMA] and G-protein-coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma [MM], with single-agent response rates from 57–71% [1,2,3,4,5,6].

Jan 24, 2024 | nature.com | Timothy Schmidt |Rafael Fonseca |Rajshekhar Chakraborty |Meera Mohan |Luciano Costa |Douglas Sborov | +1 more

AbstractExtra copies of chromosome 1q21 (+1q: gain = 3 copies, amp >= 4 copies) are associated with worse outcomes in multiple myeloma (MM). This systematic review assesses the current reporting trends of +1q, the efficacy of existing regimens on +1q, and its prognostic implications in MM randomized controlled trials (RCTs). Pubmed, Embase and Cochrane Registry of RCTs were searched from January 2012 to December 2022. Only MM RCTs were included.

Nov 26, 2023 | nature.com | Rajshekhar Chakraborty |Meera Mohan

To the editor:Bispecific antibodies (bsAbs) targeting B-cell maturation antigen (BCMA) have transformed the landscape of relapsed/refractory (R/R) multiple myeloma, with single-agent response rates of 60–70% in patients who have undergone extensive prior treatments [1,2,3]. To date, two BCMA-targeting bsAbs have received accelerated approval by the Food and Drug Administration in R/R myeloma-teclistamab and elranatamab.